Literature DB >> 15846105

Met activation and receptor dimerization in cancer: a role for the Sema domain.

Dineli Wickramasinghe1, Monica Kong-Beltran.   

Abstract

Ligand dependent activity of receptor tyrosine kinases is critical for modulating downstream signaling and cell proliferation. In normal cellular context, hepatocyte growth factor (HGF) regulates MET kinase activation and mediates cell proliferation, migration and motility. Recent elucidation of the MET extracellular domain suggests that the Sema domain, which bears structural similarity to other Semaphorins and Plexin family members, plays a critical role in ligand mediated receptor activation. Overexpression of MET which is observed in many cancers leads to ligand independent receptor dimerization and activation. Evidence to support a role for the Sema domain in cancer and therapeutic implications of targeting the Met Sema domain are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15846105     DOI: 10.4161/cc.4.5.1688

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  13 in total

1.  Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

Authors:  Daniel V T Catenacci; Les Henderson; Shu-Yuan Xiao; Premal Patel; Robert L Yauch; Priti Hegde; Jiping Zha; Ajay Pandita; Amy Peterson; Ravi Salgia
Journal:  Cancer Discov       Date:  2011-12       Impact factor: 39.397

2.  Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy.

Authors:  B Kim; S Wang; J M Lee; Y Jeong; T Ahn; D-S Son; H W Park; H-s Yoo; Y-J Song; E Lee; Y M Oh; S B Lee; J Choi; J C Murray; Y Zhou; P H Song; K-A Kim; L M Weiner
Journal:  Oncogene       Date:  2014-03-24       Impact factor: 9.867

3.  Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.

Authors:  Edward Htun van der Horst; Lawrence Chinn; Min Wang; Timothy Velilla; Hoang Tran; Yarrow Madrona; Andrew Lam; May Ji; Timothy C Hoey; Aaron K Sato
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

4.  Sema4D, the ligand for Plexin B1, suppresses c-Met activation and migration and promotes melanocyte survival and growth.

Authors:  Joanne Soong; Yulin Chen; Elina M Shustef; Glynis A Scott
Journal:  J Invest Dermatol       Date:  2011-12-22       Impact factor: 8.551

5.  Retrospective Review of MET Gene Mutations.

Authors:  Maryam Zenali; James deKay; Zesheng Liu; Stanley Hamilton; Zhuang Zuo; Xinyan Lu; Rania Bakkar; Gordon Mills; Russell Broaddus
Journal:  Oncoscience       Date:  2015-05-14

6.  Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.

Authors:  Etienne Muller; Baptiste Brault; Allyson Holmes; Angelina Legros; Emmanuelle Jeannot; Maura Campitelli; Antoine Rousselin; Nicolas Goardon; Thierry Frébourg; Sophie Krieger; Hubert Crouet; Alain Nicolas; Xavier Sastre; Dominique Vaur; Laurent Castéra
Journal:  Cancer Med       Date:  2015-07-08       Impact factor: 4.452

7.  RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.

Authors:  Zhao-Shi Bao; Hui-Min Chen; Ming-Yu Yang; Chuan-Bao Zhang; Kai Yu; Wan-Lu Ye; Bo-Qiang Hu; Wei Yan; Wei Zhang; Johnny Akers; Valya Ramakrishnan; Jie Li; Bob Carter; Yan-Wei Liu; Hui-Min Hu; Zheng Wang; Ming-Yang Li; Kun Yao; Xiao-Guang Qiu; Chun-Sheng Kang; Yong-Ping You; Xiao-Long Fan; Wei Sonya Song; Rui-Qiang Li; Xiao-Dong Su; Clark C Chen; Tao Jiang
Journal:  Genome Res       Date:  2014-08-18       Impact factor: 9.043

8.  Palmitoylation regulates the intracellular trafficking and stability of c-Met.

Authors:  David T Coleman; Alana L Gray; Steven J Kridel; James A Cardelli
Journal:  Oncotarget       Date:  2016-05-31

9.  Single-molecule photobleaching reveals increased MET receptor dimerization upon ligand binding in intact cells.

Authors:  Marina S Dietz; Daniel Haße; Davide M Ferraris; Antonia Göhler; Hartmut H Niemann; Mike Heilemann
Journal:  BMC Biophys       Date:  2013-06-03       Impact factor: 4.778

Review 10.  Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.

Authors:  Mohamed Bouattour; Eric Raymond; Shukui Qin; Ann-Lii Cheng; Uz Stammberger; Giuseppe Locatelli; Sandrine Faivre
Journal:  Hepatology       Date:  2018-02-01       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.